Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2018-12-03 Regulatory Filings
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Director Interests Notices - Appendices 3X,Y and Z 10 pages 333.6KB
Regulatory Filings
2018-12-03 English
Notice of Change of Interest of Substantial Holder 2 pages 142.2KB
Regulatory Filings
2018-12-03 English
Changes to the Board of Directors 2 pages 80.9KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 30 November 2018 regarding changes to the Board of Directors of Phylogica. It details the appointment of the CEO to the Board and the resignation of another director. There is no financial data, no mention of a report or financial results, and the content focuses solely on management changes. The document length is 3724 characters, which is relatively short and consistent with a management change announcement rather than a full report. Therefore, the document fits the category of Board/Management Information (MANG).
2018-11-29 English
FNA Presentation 11 pages 1.9MB
Investor Presentation Classification · 95% confidence The document is a presentation titled 'FNA Presentation November 2018' by Phylogica. It contains detailed slides discussing the company's technology, scientific data, and business update related to Cell Penetrating Peptides (CPPs) and their therapeutic applications. The content is structured as a presentation with visuals and explanatory notes, typical of investor or business presentations. There is no indication of formal financial statements, regulatory filings, or audit information. The document is not an announcement of a report but the presentation itself. Therefore, the most appropriate classification is Investor Presentation (IP).
2018-11-22 English
AGM Company Presentation 11 pages 1.5MB
AGM Information Classification · 95% confidence The document is titled 'AGM Presentation November 2018' and contains detailed slides about the company's technology, competitive advantages, milestones, and strategic outlook. It is structured as a presentation with visual aids and forward-looking statements, typical of materials shared during an Annual General Meeting. There is no indication of full financial statements or comprehensive annual reporting, nor is it a brief announcement or certification. The content aligns with investor presentations given at AGMs to inform shareholders about company progress and strategy.
2018-11-15 English
Chairman's AGM Address and Results of Meeting 3 pages 94.6KB
AGM Information Classification · 95% confidence The document contains the Chairman's address and summary of the 2018 Annual General Meeting (AGM) of Phylogica Limited, including strategic updates, management changes, and shareholder voting results. It explicitly references the AGM, the resolutions voted on, and proxy details. The content is typical of materials presented or disclosed in connection with an AGM, rather than a full annual report or financial statements. The document length is about 5,217 characters, which is consistent with an AGM information release rather than a full Annual Report (10-K) or Interim Report (IR). Therefore, the document is best classified as AGM Information (AGM-R).
2018-11-15 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.